12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
BenzingaApr 18 16:31 ET
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
TipRanksApr 9 06:17 ET
Biora Therapeutics Files to Sell 10.7M Common Shares for Holders
Seeking AlphaApr 8 16:26 ET
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet platform for oral, sy
BenzingaApr 8 08:02 ET
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Mean Plasma Tofacitinib Concentration Following administration of a single oral dose of 5 mg and 10 mg BT-600All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug deliver
GlobeNewswireApr 4 08:00 ET
Press Release: Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: B
Dow JonesApr 3 16:05 ET
Biora Therapeutics Full Year 2023 Earnings: Beats Expectations
Yahoo FinanceApr 1 15:39 ET
Top Midday Decliners
Eiger BioPharmaceuticals (EIGR) said Monday the company and its direct subsidiaries have filed voluntary petitions for Chapter 11 protection in the US Bankruptcy Court for the Northern District of Tex
MT NewswiresApr 1 13:58 ET
Express News | Biora Therapeutics Shares Are Trading Lower After the Company Announced a $6 Million Registered Direct Offering of 5,454,548 Shares of Common Stock at a Price of $1.10 per Share
Moomoo 24/7Apr 1 13:23 ET
12 Health Care Stocks Moving In Monday's Intraday Session
GainersSunshine Biopharma (NASDAQ:SBFM) stock rose 86.3% to $0.11 during Monday's regular session. The company's market cap stands at $11.2 million. Xilio Therapeutics (NASDAQ:XLO) stock rose 25.93% t
BenzingaApr 1 12:31 ET
Biora Therapeutics Shares Drop 26% After Pricing of Direct Offering
By Chris Wack Biora Therapeutics shares were down after the company entered into definitive agreements for the purchase and sale of 5.5 million shares at $1.10 a share in a registered direct offering
WSJApr 1 09:45 ET
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definiti
GlobeNewswireApr 1 08:00 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group
BenzingaMar 27 16:31 ET
Q4 2023 Biora Therapeutics Inc Earnings Call
Yahoo FinanceMar 27 06:18 ET
Earnings Call Summary | Biora Therapeutics(BIOR.US) Q4 2023 Earnings Conference
The following is a summary of the Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript:Financial Performance:Biora Therapeutics reported Q4 operating expenses of $13.3 million, with G&A ex
moomoo AIMar 26 20:18 ET · Conference Call
Biora Therapeutics: Q4 Earnings Insights
Biora Therapeutics (NASDAQ:BIOR) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsBiora Therapeutics missed est
BenzingaMar 26 16:45 ET
Biora Therapeutics: Remainder of BT-600 Clinical Trial Progressing Well and on Schedule >BIOR
Biora Therapeutics: Remainder of BT-600 Clinical Trial Progressing Well and on Schedule >BIOR
Dow JonesMar 26 16:15 ET
Biora Therapeutics GAAP EPS of -$0.62 Misses by $0.03
Seeking AlphaMar 26 16:12 ET
Biora Therapeutics 4Q Rev $0.00 >BIOR
Biora Therapeutics 4Q Rev $0.00 >BIOR
Dow JonesMar 26 16:09 ET
Press Release: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical
Dow JonesMar 26 16:05 ET
No Data
No Data